|
|
|
|
At follow-up,all measures of outcome in the treated and control groups were very similar.At 6 months,respective mortality rates were 37 of 107 and 33 of 109.Corresponding mean+/-DS improvements in Scandinavian Stroke Study Group scores were 8.35+/-16.9 versus 11.55+/-15.6(long-term)and 0. 64+/-7.3 versus 2.40+/-6.9(prognostic),and improvements in the Barthel Index ratings were 10.72+/-24.7 versus 13.95+/-23.3,respectively.Glasgow Coma Scale score improvements in the survivors were 0.81+/-1.5 and 1.16+/- 1.7 in the treated and control groups,respectively.Hemolysis(generally subclinical)was the only adverse effect of glycerol noted.Conclusions:In the absence of any clinically or statistically significant difference in outcome between the treated and control groups,this trial provides no justification for glycerol therapy following acute cerebral hemorrhage. |
|